Bayer AG stock (DE000BAY0017): Q1 sales up 4.1%, core EPS beats at €2.71

Bayer AG released its first-quarter 2026 results on May 12, showing group sales of €13.405 billion, a 4.1% increase on a currency- and portfolio-adjusted basis despite a negative currency impact of €886 million, according to the company press release as of 05/12/2026. EBITDA before special items climbed 9.0% to €4.453 billion, while core earnings per share advanced 12.9% to €2.71. Crop Science drove growth with nearly 7% sales increase, bolstered by €450 million in soy licensing revenue.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Bayer AG: core business model

Bayer AG operates as a life sciences company with three main divisions: Pharmaceuticals, Crop Science, and Consumer Health. The Pharmaceuticals segment focuses on prescription drugs in cardiology, oncology, and women's health. Crop Science provides seeds, crop protection products, and digital farming solutions, while Consumer Health offers non-prescription products like pain relief and dermatology items. This diversified model targets global markets, with significant exposure to the US agriculture and healthcare sectors.

In Q1 2026, Crop Science sales grew nearly 7% year-over-year to contribute strongly to group results, excluding one-time soy licensing revenue of €450 million, core growth was 1.4%, per the Q1 media update as of 05/12/2026. EBITDA margins in this division reached around 40%, supported by higher-margin sales and efficiencies.

Main revenue and product drivers for Bayer AG

Group sales for Q1 2026 totaled €13.405 billion, up 4% on a Fx & portfolio-adjusted basis, driven by Crop Science and Consumer Health, while Pharmaceuticals held steady, according to the quarterly statement published May 12, 2026 (Bayer Q1 2026 report as of 05/12/2026). Core EPS of €2.71 beat analyst expectations, as noted in Morningstar coverage as of 05/12/2026.

Free cash flow came in at negative €2.3 billion due to litigation settlement payments, in line with outlook. Net financial debt stood at €32.518 billion as of March 31, 2026, up from year-end 2025.

Industry trends and competitive position

Bayer AG holds a leading position in crop protection and seeds, benefiting from US farmer demand for high-yield products amid volatile commodity prices. In pharmaceuticals, it competes with US giants like Pfizer and Eli Lilly, with key US revenue from established drugs. The company's focus on operational efficiencies and portfolio optimization supports resilience in a high-interest-rate environment affecting US agribusiness.

Why Bayer AG matters for US investors

Bayer AG's Crop Science division generates substantial US revenue from soybean and corn seeds, tying it to American agriculture output and trade policies. Its pharmaceuticals reach US patients via partnerships and direct sales, offering exposure to healthcare spending trends without full US regulatory burden. Listed on Xetra but accessible via US ADRs, it provides diversified life sciences play for portfolios seeking European stability with US market links.

Conclusion

Bayer AG delivered a solid Q1 2026 with sales growth, EBITDA gains, and core EPS upside, led by Crop Science amid litigation cash outflows. The company reaffirmed currency-adjusted full-year guidance of €44.5-46.5 billion in sales and €4.10-4.60 core EPS. Investors track execution on strategic priorities and free cash flow recovery in coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.